Background: Vitamin B12 deficiency is common worldwide and is also linked to several diseases including autoimmune atrophic gastritis (AAG). The presence of anti-parietal cell antibodies (APCA) and/or intrinsic factor blocking antibodies (IFBA) is indicative of AAG that may develop into pernicious anemia. Both conditions are known to be associated with an increased risk of gastric carcinoma. The aim of this study was to estimate the frequency of individuals positive for APCA and IFBA antibodies in primary care patients with severe vitamin B12 deficiency. Methods: An observational study was designed and 5468 consecutive patients from primary care with a request for vitamin B12 status were included and add-on testing for APCA and IFBA that were automatically registered if severe vitamin B12 deficiency was identified (<73.8 pmol/L). For patients included in the intervention, study demographic data, mean corpuscular volume (MCV) and hemoglobin values were collected. Results: Seventy-seven patients with severe vitamin B12 deficiency were identified and out of these 44 (57%) presented with antibodies to APCA and 11 (14%) to IFBA, 25 (32.5%) had anemia, and 25 (32.5%) had macrocytosis. The majority of APCA and/or IFBA positive patients were found in the age group >70 years. Both anemia and macrocytosis were more common among APCA positive patients but the association was not statistically significant, neither was the correlation between IFBA status and anemia and/or macrocytosis. Among the patients with anemia, 10 (39%) had macrocytosis, although the rate of macrocytosis among patients with or without anemia did not differ significantly.
Introduction
Vitamin B12 deficiency is common and most often associated with a vegetarian diet lacking vitamin B12 and/or to poor absorption due to aging. The condition will inevitably continue to increase in parallel with an aging population globally. The World Health Organization suggests that vitamin B12 deficiency is a public health concern possibly affecting millions of people worldwide [1] . Prevalence in the elderly population can range between 5% and 40% [2] [3] [4] [5] [6] [7] [8] . Furthermore, common treatments in primary care, such as proton pump inhibitors and histamine-2 receptor antagonists, suppress the production of gastric acid and may lead to malabsorption of vitamin B12 [9] , thus aggravating the problem.
The clinical consequences of undiagnosed vitamin B12 deficiency are serious, including a wide range of neurological and mood disorders [10] as well as gastric adenocarcinoma [11] . The role of vitamin B12 in the erythropoiesis can be reversed when the condition is appropriately treated, as opposed to central nervous system manifestations which may persist after correction of the hematological abnormalities [12] . The latter makes detection of the deficiency in early pre-symptomatic phases crucial.
Underlying the vitamin B12 deficiency is often a silent and under-diagnosed autoimmune disorder, namely autoimmune atrophic gastritis (AAG), where the cells that produce the gastric acid in the stomach are destroyed. The onset and progression is often very slow and patients may get used to their complaints. AAG is frequently associated with other autoimmune disorders including autoimmune thyroiditis and diabetes type 1 and often considered as a pre-condition to the autoimmune disorder pernicious anemia (PA) [3, 13] . Both conditions are associated with the presence of anti-parietal cell antibodies (APCA) and intrinsic factor blocking antibodies (IFBA) as well as mucosal damage and an inability to absorb vitamin B12. There is a positive correlation between the increasing histological score of AAG and the level of both antibodies. In this context, it is important not just to identify and treat patients with vitamin B12 deficiency [14] , given the major adverse effects and potential irreversible cognitive damage of this condition [12] , but also to investigate the presence of antibodies to APCA and IFBA.
APCA and IFBA have been largely studied in patients with PA. APCA can be found in 85%-90% of such patients, but have low specificity and are seen in AAG without megaloblastic anemia [15, 16] , as well as in other autoimmune disorders [17] . APCA can also be found in approximately 8%-20% of the general healthy adult population and a fraction of these sero-positive people will never develop AAG or PA [17] . IFBA are less sensitive, being found in only 60% of patients with PA, but highly specific for the disease [18] . The prevalence of APCA and IFBA in vitamin B12 deficient patients has been less studied. As there is an excess risk for carcinoid tumors related to AAG, it is interesting to know whether and to which extent APCA and IFBA are present in patients with vitamin B12 deficiency, independently of the manifestation of anemia. However, it must be highlighted that the final diagnosis of AAG must be confirmed by the visualization of gastric atrophy trough conventional endoscopy.
The primary purpose of this investigation was to evaluate the frequency of APCA and IFBA in primary care patients with severe deficiency of vitamin B12 and correlate their presence with demographic characteristics and hematological test values.
Materials and methods

Study design
An interventional study was designed and conducted from May 1st 2017 to September 30th 2017 ( Figure 1 ). The study was approved by the Hospital Research Committee. Consecutive patients from nine primary care centers with a request for vitamin B12 status was enrolled and patients with severe vitamin B12 deficiency were included. Additional testing for APCA and IFBA, hemoglobin and MCV was performed on sera and whole blood from included patients.
Laboratory and hospital characteristics
The clinical laboratory is located in a 370-bed suburban University Community Hospital that serves a population of 234,551 inhabitants. It receives samples from inpatients, outpatients and primary care patients that are phlebotomized in nine different primary care centers. Samples are collected by couriers and delivered to the laboratory. Primary care laboratory requests are made electronically from the patient's electronic medical record (EMR) by the general practitioners (GPs) and the reports are automatically sent from the laboratory information system (LIS) to the EMR.
Participants
All community inhabitants were covered by the clinical laboratory.
Intervention design
In consensus between the laboratory and GPs, severe vitamin B12 deficiency was defined in all patients with a serum vitamin B12 level below 73.8 pmol/L [19] . Reflex testing for APCA and IFBA was performed in all samples exhibiting vitamin B12 <73.8 pmol/L for the first time. This protocol was assessed as part of a laboratory validation process. In consensus with GPs and also with gastroenterologists, for all patients with severe vitamin B12 deficiency and positivity for APCA and/or IFBA a referral to the gastroenterology department for further investigations was recommended. An automatic LIS comment was issued in the laboratory report encouraging the GP to refer the patient for a follow-up visit in gastroenterology.
Outcome measures
Demographic data, mean corpuscular volume (MCV), hemoglobin values and positivity to APCA and IFBA in the subjects diagnosed with severe vitamin B12 deficiency was studied.
Laboratory methods
Three milliliters (3 mL) of blood sample were collected from each of the subjects into BD Vacutainer ® K 2 APCA and IFBA were performed using the EliA immunoassays (EliA Parietal Cells and EliA Intrinsic Factor) on the Phadia 250 system according to the manufacturer's instructions (Thermo Fisher Scientific, Freiburg, Germany). All assays were subject to satisfactory internal and external quality control during the study.
Statistical analysis
The statistical analyses were performed with SPSS (SPSS Inc, Chicago, IL, USA). The comparative study by two percentages was done by the χ 2 -test. A two-sided p ≤ 0.05 rule was utilized as the criterion for rejecting the no difference.
Results
During the study period of 5 months, 5468 patients were screened for vitamin B12 levels and 77 new cases with severe deficiency were identified (1.4%). Of the affected patients a majority were females (67%) and the numbers increased with age. Figure 2 shows an age dependent increase in severe vitamin B12 deficiency. Positive cases doubled from 50 to 70 years and also from 70 to 80 years and only five cases were found under the age of 50 years.
Twenty-nine patients (38%) had negative results for both APCA and IFBA, while 71 were positive for one of the markers. Seven patients, all above 50 years of age, were positive for both APCA and IFBA. Four cases were positive for IFBA and negative for APCA. The number of patients positive for one of the markers in the age group 50-59 years (89%) were three times as many as the ones found in the age group 40-49 (25%). Positivity in this range was detected in approximately 50% of the patients (55% in 60-69, 52% in 70-79 and 67% in 80-89 range), suggesting that patients with severe vitamin B12 deficiency older than 50 years of age have high probability (58%) of having APCA antibodies. IFBA positivity was less frequent and more stable across all the age groups. Frequencies ranged from 11% to 29%, with the peak value at 70-79 years range (Table 1) .
No significant association between iron deficiency anemia and the presence of APCA was found in our cohort (p = 0.106) ( Table 2 ). Macrocytosis was more common in patients that were APCA positive (Table 3) , again with no significant difference (p = 0.527).
Iron deficiency and anemia, again did not statistically correlate with IFBA status (anemia [p = 0.274] and macrocytosis [p = 0.320] [ Table 4 ]).
Among the four cases positives for IFBA and negatives for APCA, that were between 70 and 79 years old, one had macrocytic anemia, two macrocytosis and one patient was negative for both. Among the seven patients being positive for APCA and IFBA, just one had anemia, that was normocytic, and two had macrocytosis. There were not significant differences in IFBA between patients with positivity and negativity in APCA (p = 0.638).
These results reinforce the evidence suggesting no significative correlation between positivity to one or both antibodies and anemia and/or macrocytosis.
Discussion
In this study more than 60% of primary care patients presenting with severe vitamin B12 deficiency had a positive test for APCA and/or IFBA. APCA and IFBA are serological markers suitable in the diagnosis of AAG, with observed specificities of 81% and 90% respectively [20] . Our data strongly suggests the presence of AAG in a majority of patients with severe vitamin B12 deficiency, and especially after the age of 50. Atrophic gastritis can have autoimmune origin but it can also appear due to Helicobacter pylori infection, and this could be one of the reasons why not all patients with vitamin B12 deficiency show positivity to the aforementioned autoantibodies.
The automated strategy implemented in our daily laboratory routine to identify subjects with a high probability of AAG that would have otherwise remained undetected seems to be efficient. This very simple approach identified patients at risk for PA and/or gastric cancer, although subsequent biopsy and histological examination must be performed in order to confirm or rule out the diagnosis. Early identification of AAG allows for simple and cheap treatment and possibly avoidance of further progress of the pathology including the serious consequences associated with both PA and gastric cancer for the patient and high economic costs for the society. It should be highlighted that the low diagnosis rate of AAG at early stages mainly is due to the Data are n (%). IFBA, intrinsic factor blocking antibodies; APCA, antiparietal cell antibodies. Data are n (%). MCV, mean corpuscular volume. Data are n (%). APCA, anti-parietal cell antibodies; MCV, mean corpuscular volume. Data are n (%). IFBA, intrinsic factor blocking antibodies; MCV, mean corpuscular volume.
lack of awareness among physicians, vague symptoms as well as subtle endoscopic and histological findings [20] . By applying the automatic LIS register under the conditions set up for the study, more than one new APCA test was found to be positive for every two tests performed. The positivity rate for the IFBA testing was lower, 11 patients among the 77 with severe vitamin B12 deficiency had a positive test result indicating a lower cost-efficiency of this determination. However, four of these patients had a single positive IFBA test that would have been missed if only APCA had been measured. In our clinical context this transforms into around 5% missed possible AAG cases, clearly indicating that both determinations are needed for optimal sensitivity and specificity.
The possibility to identify patients at an early stage of a disease through an automated intervention by using register system like LIS have major advantages for both the patient and the society. In this study the reflex testing of samples found to have vitamin B12 levels in the severe deficiency range with two markers, APCA and IFBA, associated with AAG was found to increase the identification of possible AAG cases. Instead of reporting simple data the LIS system will report back knowledge that will guide the GP in clinical decision making, like further investigations and/or a referral to a gastroenterologist.
We also studied the prevalence of iron deficiency anemia and macrocytosis in the patients that presented with antibodies to APCA and/or IFBA. No statistically significant association was found in this study although patients with positive APCA or IFBA tended to present with higher rates of anemia or macrocytosis than those that were sero-negative. Further studies in larger cohorts are needed to confirm this finding.
An additional potential implication of this study is to use a positive test result to APCA and/or IFBA to confirm the vitamin B12 deficiency. It is known that serum vitamin B12 determinations not always represent cellular status [3] and consequently is not a reliable marker of vitamin B12 status [21] , at least for moderate deficiencies. It is therefore recommended to confirm a deficient serum vitamin B12 level with a methyl-malonic acid (MMA) test. As MMA testing is not readily available in the majority of routine clinical laboratories this approach is not always applicable in daily clinical practice. However, as a positive test result to APCA and/or IFBA indicates the presence of AAG, the positivity to one or both markers would be an indirect confirmation of the deficit thus making the MMA testing unnecessary [22, 23] .
One limitation of this study is that neither MMA, total homocysteine nor holotranscobalamin have been measured to confirm the serum levels of vitamin B12.
Another limitation is that the post-study outcome has not been studied and evaluated. It is not known if APCA/ IFBA positive patients have been investigated further by endoscopy and if the additional comment regarding APCA and/or IFBA positivity in the report out of laboratory data resulted in further investigations and a potential diagnosis of AAG or other related conditions. At last, our relatively limited cohort of 77 patients was probably too small to draw conclusions regarding the relationship with APCA and IFBA and iron deficiency anemia and/or macrocytosis.
Using an automated routine laboratory strategy designed in consensus with GPs, it was found that more than 50% of patients with severe vitamin B12 deficiency also presented with antibodies to APCA and/or IFBA both highly associated with AAG. Early identification of AAG patients allow for simple and cheap treatment and avoidance of further progress into more severe stages of the disease including PA and/or gastric cancer both having serious consequences for the individual as well as high economic burden for the society. In summary, by using an integrated automated laboratory approach comprising three related diagnostic markers early diagnosis of patients at risk for PA and gastric cancer was made possible and making APCA and IFBA potential frontline markers in primary care.
